CDA and myalgic encephalomeyelitis/chronic fatigue syndrome: As expected, APH treatment significantly increased the numbers of CFS-associated UFBs in CDA-proficient and CDA-deficient cells, as shown by FANCD2 immunostaining (Supplementary Fig. 4f, g).